Nanoparticle Conjugate Vaccine

Picture
Polysaccharide-protein conjugate vaccines have been essential to prevention of bacterial infectious diseases.  This nanoparticle conjugate vaccine (NCV) platform makes use of a novel nanoparticle protein found exclusively in bacteria as the carrier protein.  It provides distinct advantages over carrier proteins used in the current conjugate vaccines.  Two NCV candidates, one for Salmonella Typhi (NCV-STY) and the other for Salmonella Paratyphi A (NCV-SPA), are being developed through preclinical studies. Both candidates are highly immunogenic in animal models.  For the NCV-SPA, non-cGMP assay and process development has been successfully completed.